FXYD5 and metastatic malignant neoplasm: Expression of dysadherin, the NKA gamma 5 subunit, has previously been shown to be a prognostic indicator for late-stage metastatic cancers.40 CD20 is best known as being a target for Rituximab and other clinically approved antibody therapies.